Insulet's Revenue in the fiscal year 2025 $ 2,708.10 millions
Insulet's Revenue in the fiscal year 2024 $ 2,071.60 millions
Insulet's Revenue in the fiscal year 2023 $ 1,697.10 millions
Insulet's Revenue in the fiscal year 2022 $ 1,305.30 millions
Insulet's Revenue in the fiscal year 2021 $ 1,098.80 millions
PODD Revenue second quarter 2026 Y/Y Growth Comment
Insulet Corporation reported Revenue improvement of 23.51% year on year in the second quarter 2026, to $ 801.70 millions, this is lower than Insulet Corporation's recent average Revenue improvement of 24.95%.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 104 other companies have achieved higher Revenue growth. While Insulet Corporation' s Revenue rise of 23.51% ranks overall at the positon no. 1787 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Insulet's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
38.44 %
6.13 %
-22.17 %
(Sep 30 2011)
PODD's II. Quarter Q/Q Revenue Comment
Insulet Corporation achieved in the II. Quarter 2026 below company average Revenue increase of 5.25% quarter on quarter, to $ 801.70 millions.
Within Medical Equipment & Supplies industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Insulet's Revenue growth quarter on quarter, overall rank is 1135.
Insulet Corporation achieved in the II. Quarter 2026 below company average Revenue increase of 5.25% quarter on quarter, to $ 801.70 millions.
Within Medical Equipment & Supplies industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Insulet's Revenue growth quarter on quarter, overall rank is 1135.
Insulet's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 3,053.40
$ 2,900.80
$ 2,708.10
$ 2,521.90
$ 2,359.50
Y / Y Revenue Growth (TTM)
29.41 %
31.92 %
30.73 %
27.12 %
25.99 %
Year on Year Revenue Growth Overall
Ranking
# 660
# 576
# 126
# 319
# 239
Seqeuential Revenue Change (TTM)
5.26 %
7.12 %
7.38 %
6.88 %
7.3 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1799
# 1636
# 573
# 1198
# 1125
Cumulative Revenue growth Comment
Assuming the Insulet's fiscal year would have ended in Jun 30 2026, Insulet would have reprted above average annual Revenue rise of 29.41% year on year, of $ 3,053 millions. This marks a slow-down of the companys growth trends and from the 31.92% improvement in Mar 31 2026.
In the Healthcare sector 136 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 576 to 660.
Assuming the Insulet's fiscal year would have ended in Jun 30 2026, Insulet would have reprted above average annual Revenue rise of 29.41% year on year, of $ 3,053 millions. This marks a slow-down of the companys growth trends and from the 31.92% improvement in Mar 31 2026.
In the Healthcare sector 136 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 576 to 660.
About Insulet Revenue Growth Rates (PODD), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
40.58%